Sanofi/Regeneron win a new trial on Praluent patents; BridgeBio bankrolls $30M biotech startup
→ After coming perilously close to seeing their PCSK9 drug Praluent jerked off the market, Sanofi and Regeneron have won a new trial in …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.